logo
Share SHARE
FONT-SIZE Plus   Neg

Teck Resources Q1 Reported Profit Down - Quick Facts

Teck Resources Ltd. (TCK_A.TO,TCK,TCK.B.TO) said its first-quarter profit attributable to shareholders as reported was C$218 million, down from C$461 million last year.

Adjusted profit rose to C$504 million from C$450 million in the prior-year quarter.

Adjusted earnings per share rose to C$0.86 from C$0.76 in the same quarter last year.

Revenues for the quarter were C$2.5 billion.

Coal production increased to 6.3 million tonnes in the quarter, up 43% from the year-ago quarter. This was the result of the successful execution of the company's ongoing expansion program. In addition, coal production in the first quarter of 2011 was negatively impacted by unusual weather- related events and a strike at the company's Elkview mine.

"Our strong first quarter results demonstrate continued solid operating performance and the successful execution of our ongoing expansion programs, particularly in coal. Gross profit was similar to the first quarter of 2011, but cash flow from operations was up 14%. Our near-term copper growth projects are on track and, with the acquisition of SilverBirch, we increased our contingent bitumen resources by 67% to 3.5 billion barrels. With a strong balance sheet and strong cash flow, we are well positioned to successfully pursue our longer term growth plans," said Don Lindsay, President and CEO.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Database startup MongoDB has filed confidentially for initial public offering, aiming to go public before the end of the year, according to TechCrunch. The company, which develops enterprise-grade, open-source software including MongoDB NoSQL database, reportedly has submitted an S-1 filing in the past few weeks. Wal-Mart Stores Inc., the world's largest retailer, reported a decline in second-quarter profit with a significant charge. Adjusted earnings topped analysts' estimates with higher comparable sales. Looking ahead, for the third quarter, the company projects earnings in line or below market view. The company also issued earnings forecast for fiscal 2018. The development of Alzheimer's drugs has been marred by a high failure rate. A U.S. study, which analyzed how the Alzheimer's clinical trials fared during the period of 2002 to 2012, revealed a failure rate of 99.6% compared to a failure rate of 81% for cancer drugs.
comments powered by Disqus
Follow RTT